glp-1 business Receptor Agonist Market Forecast Report, 2033 Langers Enters GLP-1 Market with

1 The safety and effectiveness of Wegovy injection have not been established in pediatric patients to reduce the risk of major adverse CV events, to reduce excess body weight and maintain weight reduction long term with the 7.2 mg once-weekly dosage, or to reduce excess body weight and maintain weight reduction long term in those less than 12 years of age

All of the drugs tested were shown to be safe, and several showed significant reductions in composite major adverse cardiovascular event (MACE) endpoints, which usually included cardiovascular death, nonfatal heart attack, and nonfatal ischemic stroke, compared with placebo

Kepka A et al

During the washout period, avoid UV exposure

Cognitive decline is not inevitable, but it is multi-factorial